PVLA (Palvella Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PVLA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2026-07-01 | Matthew Pauls | Director | A | — | — |
| 2026-06-22 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2026-06-16 | Matthew E Korenberg | CFO, Treasurer | M | — | — |
| 2026-06-12 | GEORGE M JENKINS | Director | A | — | — |
| 2026-06-12 | Todd C Davis | Director | A | — | — |
| 2026-06-12 | ELAINE J HERON | Director | A | — | — |
| 2026-06-12 | CHRISTOPHER P KIRITSY | Director | A | — | — |
| 2026-06-12 | Tadd S. Wessel | Director | A | — | — |
| 2026-06-12 | John Doux | Director | A | — | — |
| 2026-05-22 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2026-04-17 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2026-04-15 | John Doux | Director | A | — | — |
| 2026-04-01 | GEORGE M JENKINS | Director | Buy | — | — |
| 2026-03-20 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2026-03-02 | GEORGE M JENKINS | Director | Buy | — | — |
| 2026-03-02 | ELAINE J HERON | Director | Buy | — | — |
| 2026-02-20 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2026-02-09 | Ashley Hartmann Kline | Chief Commercial Officer | A | — | — |
| 2026-02-09 | Kathleen Goin | Chief Operating Officer | A | — | — |
| 2026-02-09 | Matthew E Korenberg | CFO, Treasurer | A | — | — |
| 2026-02-09 | Jeffrey S Martini | Chief Scientific Officer | A | — | — |
| 2026-02-09 | Wes Kaupinen | President and CEO | A | — | — |
| 2026-01-23 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2025-12-19 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2025-11-21 | Kathleen Goin | Chief Operating Officer | MIXED | — | — |
| 2025-06-11 | CHRISTOPHER P KIRITSY | Director | A | — | — |
| 2025-06-11 | GEORGE M JENKINS | Director | A | — | — |
| 2025-06-11 | ELAINE J HERON | Director | A | — | — |
| 2025-06-11 | Todd C Davis | Director | A | — | — |
| 2025-06-11 | Tadd S. Wessel | Director | A | — | — |
| 2025-06-03 | Ashley Hartmann Kline | Chief Commercial Officer | A | — | — |
| 2025-04-10 | GEORGE M JENKINS | Director | Buy | — | — |
| 2025-02-10 | Jeffrey S Martini | Chief Scientific Officer | A | — | — |
| 2025-02-10 | Matthew E Korenberg | CFO and Treasurer | A | — | — |
| 2025-02-10 | Wes Kaupinen | President and CEO | A | — | — |
| 2025-02-10 | Kathleen Goin | Chief Operating Officer | A | — | — |
| 2025-02-07 | PALVELLA THERAPEUTICS, INC. | CFO and Treasurer | A | — | — |
| 2025-02-07 | PALVELLA THERAPEUTICS, INC. | Chief Operating Officer | A | — | — |
| 2025-02-07 | PALVELLA THERAPEUTICS, INC. | President and CEO | A | — | — |
| 2025-02-07 | PALVELLA THERAPEUTICS, INC. | Chief Scientific Officer | A | — | — |
| 2024-12-19 | GEORGE M JENKINS | Director | Buy | — | — |
| 2024-12-17 | Matthew E Korenberg | CFO, Treasurer | A | — | — |
| 2024-12-17 | Jeffrey S Martini | Chief Scientific Officer | A | — | — |
| 2024-12-17 | Tadd S. Wessel | Director | A | — | — |
| 2024-12-17 | GEORGE M JENKINS | Director | A | — | — |
| 2024-12-17 | ELAINE J HERON | Director | A | — | — |
| 2024-12-17 | Kathleen Goin | Chief Operating Officer | A | — | — |
| 2024-12-17 | Wes Kaupinen | President and CEO | A | — | — |
| 2024-12-17 | CHRISTOPHER P KIRITSY | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | — | 282,223 | — |
| — | Director | 201,132 | — |
| — | Director | 53,691 | — |
| — | Chief Operating Officer | 4,302 | — |
| — | CFO, Treasurer | 1,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PVLA quote page; the site-wide leaderboard is on the insider transactions hub.